Entries by Nancy McNamara

Drug Development

Our understanding of the causes of cancer informs our efforts to develop effective therapies.  Mutations of the BRAF gene that result in an aberrant KIAA1549-BRAF fusion protein and subsequent dysregulation of the RAS/RAF/MEK signaling pathway occur in a large number of pediatric low-grade gliomas.  This pathway is therefore a good candidate pathway for therapeutic targeting. […]


Mutations within our DNA are largely responsible for tumorigenesis, whether inherited or acquired by cells.  Pratiti Bandopadhayay, PhD, MBBS and Rameen Beroukhim, MD, PhD, are focused on the genomic characterization of different cancer types, and the development of novel methods to analyze the large datasets generated from these studies. Drs. Bandopadhayay and Beroukhim identified the MYB-QKI genetic […]